Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
Regeneron stock drops double digits on oncology trial failure
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal late-stage clinical trial. The sharp selloff followed Regeneron's announcement that its high-dose fianlimab and cemiplimab combination failed to significantly outperform Merck's Keytruda in a Phase 3 study involving patients with previously untreated metastatic melanoma.
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation.
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has prompted a wave of analyst downgrades. The company disclosed on Friday that its phase 3 trial of fianlimab, combined with its approved immunotherapy cemiplimab, as a first-line treatment for advanced melanoma did not reach statistical significance on its primary goal of improving progression-free survival compared with Merck's established cancer drug Keytruda.
Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Shares tumbled premarket after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Regeneron shares slide despite Q1 beat
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares fell more than 5.5% on Wednesday morning even as the drugmaker reported better-than-expected first-quarter results and announced a new share repurchase program worth up to $3 billion. Revenue rose 19% year-over-year to $3.605 billion for the quarter ended March 31, while adjusted earnings came in at $9.47 per share, both topping Wall Street forecasts of $3.49 billion and $8.94 per share respectively, according to LSEG data cited by Reuters.
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates
Regeneron (REGN) came out with quarterly earnings of $9.47 per share, beating the Zacks Consensus Estimate of $8.52 per share. This compares to earnings of $8.22 per share a year ago.
